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Abstract
Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease state,
characterised by progressive airflow limitation that is not fully reversible. Although COPD is
primarily a disease of the lungs there is now an appreciation that many of the manifestations of
disease are outside the lung, leading to the notion that COPD is a systemic disease. Currently,
diagnosis of COPD relies on largely descriptive measures to enable classification, such as symptoms
and lung function. Here the limitations of existing diagnostic strategies of COPD are discussed and
systems biology approaches to diagnosis that build upon current molecular knowledge of the
disease are described. These approaches rely on new 'label-free' sensing technologies, such as high-
throughput surface plasmon resonance (SPR), that we also describe.
Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a treat-
able and preventable condition characterised by progres-
sive airflow limitation that is not fully reversible [1].
COPD is associated with an abnormal inflammatory
response of the lungs to noxious particles or gases. This is
primarily caused by tobacco smoking [2,3] but there is
gathering evidence that additional factors predispose
patients to COPD, such as genetic susceptibility, air pollu-
tion and other airborne irritants [4,5]. There may well be
a genetic predisposition and also some food preservatives
have also been implicated indicating that the underlying
causality of the disease may not just reside in lung insult
from the atmosphere [6]. COPD is projected to have a
major effect on human health and worldwide by 2020 it
is predicted to be the third most frequent cause of death
[7].
COPD consists of three main respiratory pathologies;
emphysema, respiratory bronchiolitis and chronic bron-
chitis. These separate and distinct pathologies illustrate
the heterogeneity of COPD [8] and the importance of well
defined COPD phenotypes [9]. Although COPD is prima-
rily a disease of the lungs there is now an appreciation that
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many of the manifestations of disease are outside the
lung, such as cachexia, skeletal muscle dysfunction, cardi-
ovascular disease, depression and osteoporosis [10], lead-
ing to the concept that COPD is a systemic disease [11-
15].
Current Methods for Confirming a COPD 
Diagnosis
The diagnosis of COPD is based on the presence of typical
symptoms of cough and shortness of breath, together with
the presence of risk factors, and is confirmed by spirome-
try. A variety of methods (as outlined in Figure 1) are then
used to classify the severity of disease, including question-
naires, GOLD and BODE Index.
The Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) classifies COPD into four stages; mild, mod-
erate, severe and very severe according to spirometric
measurements [16]. Spirometry, however, is believed to
correlate poorly with symptoms [17], quality of life [18],
exacerbation frequency [19] and exercise intolerance [20].
A more recent and comprehensive method for assessing
disease severity and prognosis of COPD is the BODE
Index. This is a multidimensional grading system, which
not only measures airflow obstruction (FEV1), but also
incorporates body mass index (BMI), dyspnoea score and
exercise capacity [21]. A comparison between the BODE
and GOLD classifications shows that the BODE is a better
predictor of hospitalisation [22] and death [21] than by
GOLD.
There are conflicting views on the prevalence of COPD
ranging from 3–12% [23] to 50% [24]. A major contribut-
ing factor to this may be that only one-third of physicians
know the correct spirometric criteria according to GOLD
[25] and only one-third of trained GPs and nurses trust
their own spirometric interpretive skills [26]. Addition-
The main methods currently used by clinicians to classify the severity of COPD Figure 1
The main methods currently used by clinicians to classify the severity of COPD.Respiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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ally, the technical limitations of the instruments used to
undertake these spirometric measurements such as instru-
ment variation and signal-to-noise ratio need to be con-
sidered [27,28]. Although spirometry is generally used to
measure airflow obstruction, it has a number of limita-
tions with regard to the detection and assessment of dis-
ease. Spirometry measures established airflow
obstruction, which is likely to result from a long and con-
tinuous inflammatory process. Early use of therapeutic
interventions, however, may be most helpful in attenuat-
ing the development of airway obstruction, which is not
identifiable by spirometric tests. A single FEV1 measure-
ment will give information on how much airway obstruc-
tion has already occurred, but will not give any
information as to the current level of disease activity. At
present, such information can only be obtained by serial
measurements and assessment of the reduction in FEV1
over time. Finally, spirometry measures the end result of
what may be a number of disease processes. It is known
that patients vary considerably in their response to treat-
ments, for example to inhaled corticosteroids [29], and it
is possible that there are a number of pathways by which
smoking and other exposures lead to the final state of
COPD. An alternative diagnostic approach may help iden-
tify disease subtypes and allow for a more accurate distinc-
tion between COPD and chronic irreversible asthma [30].
Biomarker Identification
In an effort to identify biomarkers of COPD, several
groups have looked at genetic susceptibility (single nucle-
otide polymorphisms; SNPs), gene expression or protein
expression. The observations from these studies have pro-
vided useful information and insights into the pathogen-
esis of COPD.
Genetic susceptibility
As previously mentioned, COPD is associated with an
abnormal inflammatory response of the lungs to noxious
particles or gases. Due to the diverse response to these
environmental insults, it is likely that genetic factors are
important within the aetiology of COPD [31], but only
severe alpha 1-antitrypsin deficiency is a proven genetic
risk factor for COPD [32].
To date, studies have taken one of two approaches; they
have either focused on candidate genes such as CCL5 [33]
or taken a more holistic approach and completed
genome-wide linkage analysis studies to identify regions
of the genome that confer susceptibility [34]. The major
considerations with any genetic study, however, are the
large size required and the need for replication in a differ-
ent, large data set. Using the focused approach Chappell
et al have identified six haplotypes of the SERPINA1 gene
that increases the risk of disease [35]. A recent genome-
wide linkage analysis performed by Hersh et al identified
a region on chromosome 1p that showed strong evidence
of linkage to lung function traits [36]. Association analysis
then identified TGFBR3 (betaglycan) as a potential sus-
ceptibility gene for COPD, which is supported by both
murine and human microarray data.
Gene Expression
Several researchers have examined gene expression pro-
files in an attempt to identify biomarkers, distinguish dis-
ease sub-types and generate candidates for further genetic
and biological studies [37-45].
Spira et al reported genome-wide expression profiling of
subjects with severe emphysema undergoing lung volume
reduction surgery, which identified gene expression mark-
ers for severe emphysema as well as positive response to
surgery [44]. Golpon et al used a similar approach and
identified gene expression biomarkers distinguishing
patients with α1-antitrypsin deficiency [41]. Pierrou and
colleagues have identified a gene set of 200 transcripts
dysregulated in COPD compared to healthy smokers [37].
As with most disease-focused microarray studies, how-
ever, there has been a lack of consistency in the identifica-
tion of COPD gene expression biomarkers. For example,
Egr-1 was identified in a microarray study as a gene over-
expressed in emphysema subjects by Zhang et al [46]. Sub-
sequently, Ning et al, using a combined microarray/SAGE
approach, validated Egr-1 induction associated with
COPD severity [40]. Ning et al went on to show that Egr-
1 appears to contribute to disease pathogenesis, as it can
regulate matrix-remodelling potential through fibroblast
protease production. Bhattacharya et al, however, found
no evidence of differential expression for Egr-1 in their
population, although this study is one of the most prom-
ising to date, as the authors have presented the first gene
expression biomarker for COPD validated in an inde-
pendent data set [45]. This study, however, still has limi-
tations, mainly due to the size of the sample population.
Overall, there is minimal overlap between differentially
expressed genes among the different datasets. This prob-
lem highlights the complexity of expression profiling
analysis in a human disease, such as COPD, with tissue
heterogeneity and variable clinical phenotype. The non-
overlapping gene datasets from these studies are due to
several factors, including differences in sample acquisi-
tion, disease severity, sample size, tissue and cell compo-
nents, and expression platforms [39].
Protein Expression
Numerous groups have looked at protein expression, but
most studies, due to technology limitations, have only
analysed a limited set of proteins [47-52]. Shaker and col-
leagues examined six plasma proteins of known potential
interest in COPD by enzyme-linked immunosorbantRespiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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assay (ELISA) [48]. From this extremely selective reduc-
tionist approach they were able to show that some pro-
teins were up-regulated and some were down-regulated,
which emphasises the need for a more holistic approach
to deliver a molecular fingerprint of disease. A larger scale
analysis of proteins in COPD has been undertaken using
two different techniques. Plymoth et al, by using a combi-
nation of replicate 2-dimensional gel separations, image
annotation, and mass spectrometry identification, were
able to investigate 406 proteins in bronchoalveolar lavage
(BAL) that had the potential to identify smokers at risk of
developing COPD [49]. These proteins showed expres-
sion patterns that were both up- and down-regulated.
Pinto-Plata et al went a stage further and used serum on a
'Protein Microarray Platform' (PMP), which provided
data on 143 serum proteins of potential interest [50]. This
highlighted 24 proteins, which were up-regulated in dis-
ease, but it was acknowledged by the authors that the
study was a proof of principle rather than a comprehen-
sive analysis of all possible biomolecules related to
COPD.
Systems Biology: A New Approach to Disease 
Diagnosis and Management
Despite intensive research, definitive single disease-defin-
ing biomarkers for COPD remain elusive. Molecules
shown to have a significant correlation with disease status
often fail to accurately discriminate COPD from closely
related diseases that display similar symptoms. As such,
many of the potential biomarkers that have been sug-
gested for COPD, including proteins [50,51,53],
cytokines [48,50,54-65], antibodies [66], enzymes
[50,67-69] and inhibitors [48], have also been implicated
as potential targets in other lung diseases or general sys-
temic inflammation [70-116] (Table 1). The difficulties
encountered whilst searching for COPD biomarkers may
be due in part to the complex nature of the disease, which
comprises a broad spectrum of histopathological findings
and respiratory symptoms [45]. Consequently, the proba-
bility of finding a single marker that is representative of all
these processes is rather unlikely. Identification of single
biomarkers is also hindered by the high level of variability
in normal protein concentrations amongst individuals.
This makes it difficult to establish the concentration of a
single mediator that indicates disease onset [117,118].
Thus, it is essential to put isolated readings into context,
i.e., does an elevated protein concentration indicate the
presence of disease, or is it just a high but otherwise nor-
mal reading?
The problems encountered with biomarker identification
are not unique to COPD. Whilst the focus of biomarker
studies over the last decade or so has primarily been
placed on the use of individual molecular biomarkers as
indicators of disease, this approach has only proved suc-
cessful for a limited number of diseases including prostate
and breast cancer where measurements of prostate specific
antigen (PSA) and human epidermal growth factor recep-
tor 2 (HER2) respectively are routinely used in diagnostic
procedures [119,120]. New approaches to disease diagno-
sis in general, therefore, are required.
Systems biology is a broad new paradigm that has recently
entered the terminology of the life and biomedical sci-
Table 1: Potential COPD biomarkers and other diseases in which they have been implicated.
Potential COPD biomarker Also implicated in References
Clara cell protein-10/16 Cystic fibrosis, general lung injury, lung cancer [51,70,71]
C-Reactive Protein Lung cancer, asthma [50,72,73]
Endothelin-1 Asthma, idiopathic pulmonary fibrosis, lung cancer, heart disease [53,74]
IFN-gamma Pulmonary sarcoidosis, viral infections [54,75,76]
IgG Asthma, rheumatoid arthritis [66,77,78]
IL-1 Rheumatoid arthritis, leukaemia [55,79-81]
IL-4 Severe asthma [56,82,83]
IL-6 Sarcoidosis, lung cancer [57,84,85]
IL-8 Asthma, lung cancer, idiopathic interstitial pneumonia, sarcoidosis [48,85-88]
IL-10 Burkitt lymphoma, asthma, sepsis [58,89-91]
IL-12 Crohn's disease, systemic lupus erythematosus [59,60,92,93]
IL-13 Asthma [61,62,94,95]
IL-18 Asthma, sarcoidosis [63,96,97]
IP-10 Sarcoidosis, asthma, SARS, tuberculous pleurisy [64,98-101]
MMP-2 Lung cancer, asthma [67,102-104]
MMP-12 Lung fibrosis, lung cancer [68,105-107]
Myeloperoxidase Lung cancer, cystic fibrosis [69,108,109]
Neutrophil elastase Systemic inflammatory response syndrome, lung cancer, cystic fibrosis [50,110-112]
TIMP-1 Lung cancer, heart disease, asthma [48,102,113,114]
TNF-alpha Virus induced inflammation, HIV, asthma [50,65,76,115,116]Respiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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ences arena. It is an integrative approach focused on deci-
phering the relationship and the interactions between the
gene, protein and cell elements of a biological system and
how they impact on the function and behaviour of that
system [121] (Figure 2). Traditional '-omics' fields, includ-
ing genomics, proteomics, metabolomics and transcrip-
tomics examine only one strand of the information
available about an organism. Systems biology combines
data from all these fields with bioinformatic, computa-
tional biology and engineering principles to examine
organisms as systems of interconnecting networks. These
networks will be modelled according to initial data
obtained by traditional '-omics' and then revised through
a combination of iterative refinement and bootstrapping
(repeated random samples taken from a dataset) as
described by Aderem [122] and Lucas [123]. By studying
complex biological systems in this way, it is possible to
identify emergent properties that are not demonstrated by
individual '-omics' fields and cannot be predicted even
with full understanding of the parts alone. A comprehen-
sive understanding of these emergent properties requires
systems-level perspectives not obtainable using simple
reductionist approaches [122].
Studies have started to apply systems biology approaches
and principles to decipher the pathways underlying com-
plex diseases including Alzheimer's disease [124], polyar-
ticular juvenile idiopathic arthritis [125], psychiatric
disorders [126] and Sjögren's syndrome [127]. Applica-
tion of the integrative approach provided by systems biol-
ogy seems to offer a better route to understanding disease
[128,129]. Currently, our understanding of systems biol-
ogy is reaching a point whereby patterns of molecular
behaviour are far clearer indicators of pathophysiological
conditions than individual molecular markers [129]. Each
disease possesses a unique molecular fingerprint that
could be used diagnostically to differentiate it from dis-
eases with closely related phenotypes. This novel concept,
whilst still in its infancy, is being applied to cancer diag-
nosis [130] and is ideal for diagnosis of other complex
diseases such as COPD.
Identification of a COPD-specific molecular fingerprint is
a sizeable problem due to the heterogeneity of the disease
and represents a huge undertaking. Different disease sub-
types would each display slight, but measureable, varia-
tions of an overall COPD fingerprint. This fingerprint
would also need to be sensitive enough to discriminate
between COPD and other respiratory diseases e.g. chronic
asthma, many of which display similar symptoms.
Initially, the COPD-specific molecular fingerprint would
comprise biomolecules already associated with the dis-
ease, such as the RNA and protein molecules previously
mentioned. Whilst these are the most well characterised
disease targets, other molecular species may eventually
form an integral part of a disease-specific molecular fin-
gerprint. Targets such as SNPs [131], miRNA [132,133]
and post-translational modifications [134,135] have all
been shown to be important in disease pathology. Thus, a
disease-specific molecular fingerprint would be a dynamic
model that could be adapted to include such targets as
new evidence becomes available of their involvement in
COPD.
Current Analytical Technologies
The feasibility of identifying disease-specific biomolecular
patterns has been enhanced by the recent advent of pro-
teomic and genomic technologies. Multi-parametric tech-
nologies, including bead-based assays (i.e., Luminex and
Cytokine Bead Arrays), 2D gel electrophoresis, microarray
platforms (both DNA and protein) and mass spectrome-
try, have provided the opportunities for a more holistic
approach not previously possible using conventional
technologies such as the enzyme-linked immunosorbent
assay (ELISA) [136-140]. The implementation of these
high-throughput technologies has vastly increased the
prospects of biomarker research as they facilitate simulta-
neous analysis of multiple (often tens of thousands)
potential biomarkers in minimal sample volumes with
the potential for identifying novel targets not previously
associated with the disease of interest. As such, they will
be vital during the extremely complex task of identifying
and revising disease-specific molecular fingerprints.
Systems Biology: beginning to piece together the life sciences  puzzle Figure 2
Systems Biology: beginning to piece together the life 
sciences puzzle.
Genes Proteins
RNA
Small molecules 
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Employment of systems biology approaches in routine
diagnostic procedures, however, would require the availa-
bility of technologies that allow simultaneous detection
of different molecular species e.g. both genes and pro-
teins. The major disadvantage with the aforementioned
techniques is the ability to detect only a single molecular
species at once. Limitations with traditional proteomic
and genomic technologies, particularly ELISA- and fluo-
rescence-based systems, would be prohibitive to the pro-
duction of systems that simultaneously detect multiple
types of biomolecule. Such difficulties, including reagent
limitations, the need for lengthy and complicated labe-
ling, incubation and detection procedures and the poten-
tial for steric hindrance caused by the label at the binding
site, could all be circumvented by the use of label-free
technologies [141-143] such as surface plasmon reso-
nance (SPR).
Surface Plasmon Resonance (SPR)
What is SPR?
Surface plasmon resonance (SPR) polaritons are surface
electromagnetic waves that propagate in a direction paral-
lel to the interface between the metal surface and the
external medium e.g., liquid. Since the wave exists on the
boundary of the metal and the external liquid medium,
these oscillations are very sensitive to any change of this
boundary, such as the adsorption of molecules to the
metal surface. This phenomenon enables the label-free,
real-time detection of the interaction of biological mole-
cules to the metal surface (usually gold) [144]. One fre-
quently used configuration of the technology comprises a
glass surface, coated with a thin gold film, which is
attached to a prism (Figure 3). Chemical modification of
the gold surface allows for the attachment of ligands for
many different biomolecules [145-148]. Polarized light
from a laser or other light source interacts with the gold
surface at an angle greater than the critical angle (θ).
Above this angle the light is coupled to electrons in the
gold surface resulting in the propagation of surface plas-
mons along the surface. A surface plasmon only pene-
trates a short distance into the external medium (e.g., the
aqueous environment in a flow cell) making it highly sen-
sitive to changes on the surface of the gold but largely
unaffected by processes in the bulk medium. Changes on
the surface due to binding events can be readily moni-
tored and have the potential to be used to measure con-
centrations, ligand-receptor binding affinities and
association-dissociation kinetics of potentially thousands
of proteins and genes rapidly and simultaneously [143].
The use of SPR for the detection of biomolecules
The single great virtue of using SPR-based detection
modalities is that they are label-free and thus do not
require anything more for their identification apart from
selective recognition on an appropriate chip surface. Cou-
pling the appropriate surface chemistry for ligand attach-
ment with SPR would allow detection of virtually any
species of biomolecule. If the correct capture molecule is
selected, SPR is specific enough to distinguish between
different glycosylated forms of an antibody [149]. This
flexibility, coupled with the potential for increased sensi-
tivity [150], has led to an upsurge in the use of SPR tech-
nology. SPR has traditionally been used for identification
of protein binding partners and characterisation of bind-
ing events [151-156]. It has been applied to the discovery
and development of potential therapeutic agents [157-
159] and characterisation of interactions between these
compounds and their targets [160,161]. Additionally, it
has been used to characterise the molecules, biochemical
interactions and processes that may play a role in disease
pathology [162-165].
More recently SPR has emerged as a powerful platform for
biomarker studies and has been employed in the meas-
urement of many biomolecules implicated in disease
(Table 2). SPR detection systems have now been deployed
in assays for a wide range of biomolecular species includ-
ing proteins [166-172], antibodies [173], SNPs [174], sug-
ars [175,176], narcotics [177,178], peptides [179,180],
small molecules [181] and microRNAs [182]. These
biomarkers have been identified within multiple types of
clinical sample including mock samples [183], plasma
[173,184-188], serum [189] and saliva [181,190]. Several
of the studies mentioned in Table 2 have used SPR to
detect biomarkers at clinically relevant concentrations
highlighting the feasibility of using SPR in a clinical set-
ting. For example, Nagel et al have been able to differenti-
Outline of a Surface Plasmon Resonance (SPR) system utilis- ing a Kretschman-Raether configuration Figure 3
Outline of a Surface Plasmon Resonance (SPR) sys-
tem utilising a Kretschman-Raether configuration. A 
system with this configuration facilitates label-free detection 
of biomolecules that bind in real-time. Biomolecules within 
the sample bind to ligands immobilised on the gold surface 
causing a change in the levels of the surface plasmon signals. 
Analysis of this change enables determination of both kinetic 
and analyte concentrations.Respiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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ate Lyme borreliosis infected patients from healthy
donors by SPR analysis of Lyme borreliosis specific anti-
bodies in blood serum samples [188]. Cho et al used SPR
detection of CSFV antibodies to identify pigs infected with
classical swine fever [191]. Vaisocherova et al devised an
SPR assay for detection of the candidate pancreatic cancer
marker activated cell leukocyte adhesion molecule
(ALCAM) that can be used to distinguish between ALCAM
levels in cancer and control sera [192]. The measurements
made during the latter two studies were demonstrated to
have comparative specificity and sensitivity to those
undertaken with classical detection techniques [191,192].
SPR, however, has the additional benefits of being label-
free, requiring no amplification step, having low sample
requirement and high reusability, and requiring no sam-
ple pretreatment [192,193]. These advantages will in turn
result in decreased experimental time, increased cost effi-
ciency and simplification of detection protocols allowing
lower user proficiency.
Systems Biology Approaches to COPD 
Diagnosis – Implementation of a working COPD 
specific microarray chip
The principles of SPR, when combined with the use of an
imaging step (SPR imaging; SPRi), allows a gold surface to
be prepared in an array format providing the opportunity
to study thousands of interactions rapidly and simultane-
ously [194]. SPRi could be employed in the development
of a COPD specific microarray chip onto which ligands to
the biomolecular components of the COPD-specific
molecular fingerprint are arrayed (Figure 4). This diagnos-
tic test examining levels of the biomolecules within the
COPD molecular fingerprint would transform the accu-
racy, reliability and reproducibility of COPD diagnosis
Table 2: Disease-specific biomarkers detectable by SPR
Disease Target molecule Reference
Cancer Activated leukocyte cell adhesion molecule [168]
Ferritin [193]
Transgelin-2 [168]
Cystatin C [166]
Cardiovascular disease B-type natriuretic peptide [187]
C-reactive protein [169]
Cystic Fibrosis W1282X mutation [174]
Hepatocellular tumors Alpha-fetoprotein [185]
Inflammatory disease Cystatin C [166]
Lyme borreliosis Pathogen specific antibodies [188]
Myocardial infarction Cardiac troponin I [170,186,189]
Myoglobin [170,186]
Osteoporosis N-telopeptide [179,180]
Prostate cancer Prostate specific antigen [171,172]
Type 2 diabetes Retinol binding protein 4 [184]
Viral meningitis Beta2-microglobulin [166]
A schematic representation demonstrating how a COPD- specific SPR microarray chip could be employed Figure 4
A schematic representation demonstrating how a 
COPD-specific SPR microarray chip could be 
employed. A small blood sample would be required, which 
would be separated into serum and cellular components 
using a microfluidic approach. Varying gene and protein 
expression would be monitored by changes in SPR enabling 
label free detection.Respiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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and assessment. We discuss below the broad methodol-
ogy of the chip design and analytical implementation that
offers much promise with disease detection and manage-
ment.
Target molecules
Initially the COPD specific microarray chip would be
arrayed with antibodies, oligonucleotides and antigens as
there is evidence of their ligands (proteins, RNA and anti-
bodies respectively) being dysregulated in COPD [55,195-
197]. Whilst the level of complexity of a biological system
is vast, incorporating multiple cellular, genetic and molec-
ular components, current approaches to disease-specific
pattern analysis focus on deciphering panels of only one
molecular component i.e., protein or mRNA
[50,198,199]. For a more comprehensive depiction of the
disease state, however, simultaneous examination of both
the mRNA and protein levels of a molecule is vital as evi-
dence suggests that correlation between the two can be
poor [200,201]. In a study examining mRNA and protein
expression in lung adenocarcinomas, only 21.4% of genes
showed significant correlation with their corresponding
protein [201]. Thus, both the mRNA and protein species
of a molecule will be examined even if only one of these
has been associated with disease. As the molecular finger-
print of COPD is further refined, the repertoire of detec-
tion would be adapted to allow for detection of single
nucleotide polymorphisms (SNPs), microRNAs, peptides,
enzymes/substrate interactions, small molecules (e.g.
serotonin, vitamins, histamine), sugars or cell surface
markers as appropriate.
Clinical sample type
Another important factor to consider is the source of clin-
ical sample being examined. Samples traditionally exam-
ined in cases of respiratory disease include induced
sputum, BAL, lung tissue and, more recently, exhaled
breath condensate (EBC). All of these sample types could
potentially be analysed for patterns of biomarkers, but
they are hindered by their invasiveness, cost or high level
of variability [202]. The systemic manifestations of many
complex diseases, including COPD [11,12], make analysis
of body fluids an appealing option. In particular, the
dynamic nature of blood means that it reflects the diverse
physiological or pathological states of an individual. Cou-
pled with its comparative ease of sampling, this makes the
analysis of blood components the ultimate target for
biomarker applications. Utilising blood samples would
provide the opportunity to examine a full spectrum of
molecular and cellular components within the disease-
specific fingerprint including (but not exclusively) soluble
proteins [50], cell types [203], cellular proteins/markers
[204], autoantibodies [205], post-translational modifica-
tions [206] and circulating nucleic acids [207,208]. The
proposed use of whole blood as a sample would require
steps for separation on the basis of size and the ability to
lyse cells to extract intracellular components. This could
be achieved by coupling a microfluidic system, such as
that previously described [209], to the chip to allow in-situ
separation of the blood sample into plasma and cellular
components.
Despite the huge potential of blood samples in diagnostic
tests, some major challenges with its implementation
need to be overcome. Past investigations into plasma
biomarkers have been hindered by the fact that the
plasma proteome is dominated by several highly abun-
dant proteins, which mask proteins of much lower abun-
dance identified as contributing to disease states [210-
212]. This is not a trivial problem even in cases in which
highly selective molecular-recognition-based protein
identification technologies, such as those which are anti-
body-based, are employed. It is also important to consider
other factors that may affect serum protein levels includ-
ing psychological stress, time of blood sample collection,
time since last meal, or uncontrolled differences in speci-
men handling [213,214]. Many of these limitations are
beginning to be addressed [215,216] increasing the feasi-
bility of comprehensive diagnostic testing in plasma. To
this end, preliminary studies examining patterns of bio-
molecules, including proteins and autoantibodies, have
been undertaken with some success for diseases such as
graft versus host disease [217], chronic pancreatitis [198],
brain cancer [218], lung cancer [219,220] and idiopathic
pulmonary fibrosis (IPF) [221].
With regards to COPD, there is preliminary evidence that
patterns of biomarkers in the peripheral compartment
could be used to distinguish patients with COPD.
Increased concentrations of TNF-α and IL-6 have been
demonstrated in the serum of stable COPD patients
[222]. Pinto-Plata et al used a protein microarray platform
to identify 24 serum proteins that were up-regulated in
COPD [50] whilst Shaker et al demonstrated that down
regulation, as well as up-regulation, of plasma proteins
was indicative of COPD [48]. Man et al took this one step
further and demonstrated that ratios of blood biomarkers,
in this case fibronectin and CRP, are significantly associ-
ated with all-cause mortality of COPD patients [52].
Whilst such studies should be considered a proof of prin-
ciple rather than a comprehensive analysis of all possible
biomolecules related to COPD, this data provides evi-
dence that a systems biology approach to COPD diagnosis
and evaluation is attainable within blood. Additionally,
whilst forming a complex network of interaction in the
lung, all the potential COPD biomarkers identified in
Table 1 have been detected within blood (Figure 5),
although this has not always been in the context of
COPD. These molecules, combined with those identified
by the aforementioned studies, could provide the basis ofRespiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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Schematic representation of key molecules associated with COPD in the lung and periphery Figure 5
Schematic representation of key molecules associated with COPD in the lung and periphery. Analysis of these 
molecules at both the protein and gene level would form the basis of a molecular fingerprint of COPD for use in disease diag-
nosis.Respiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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a prototype peripheral compartment COPD molecular
fingerprint.
Defining, revising and analysing a molecular fingerprint
In addition to developing hardware with exquisite molec-
ular sensitivity, the key to implementing advanced detec-
tion modalities is to include analytical protocols that are
able to recognise complex biomolecular patterns made up
of different molecular species and relate these to the dis-
ease condition under consideration e.g., COPD. Such ana-
lytical models now typically involve Bayesian inference
approaches often starting with the hidden Markov model
(HMM). This is essentially the simplest dynamic Bayesian
network in which the system being studied is assumed to
be a Markov process with unknown parameters. The chal-
lenge is to determine the hidden (i.e., disease) parameters
from the observable molecular data so that the target con-
dition of COPD can be identified. The Bayesian approach
is particularly helpful with determination of the probabil-
ity that any 'positive' result is actually a false positive. A
systems biology approach to disease diagnosis strives to
identify the presence of a molecular fingerprint of biomol-
ecules that is not typically normal. Thus an observed bio-
molecular pattern from a suspected COPD patient is
compared to a standardized 'healthy' pattern and diag-
nosed as having COPD or not. This approach is much
more powerful than a diagnosis based on the presence of
an altered concentration of a singular molecular marker
e.g., PSA as it is less susceptible to the large variations in
molecular marker concentration that naturally occur in
any given population. The holistic measurement of a bio-
molecular pattern is more likely to reflect a disease condi-
tion than an individual molecular marker and, therefore,
would augment the detection process. We are not alone in
this vision, as others have also adopted this strategy as a
way forward in molecular analysis. Alagaratnam et al are
utilising Bayesian approaches to pursue muscular dystro-
phy diagnosis [223]. Similarly, the example we use above
regarding PSA is also addressed using a systems analysis
based on pattern-matching algorithms by groups in the
US [224]. The problems with all these approaches how-
ever, are that they mostly rely on mass spectrometry for
the molecular measurement and as such are expensive,
require a significant investment in operator-skill and are
less high-throughput than the SPR methodology we
describe above. The latter point is extremely important if
community screening is to be employed. Similarly, Baye-
sian approaches are not the only ways forward in mining
the profile information. Other groups have discussed
these approaches so we do not cover this in this review
[225-227], but emphasise that it is the patterns of data
that are important and not individual measurements.
These analytical approaches are not just exclusive to the
biomedical sciences as pattern analysis is central to much
image analysis and recognition, such areas could well
offer rich sources of analytical protocols.
Potential Benefits
Adopting an SPR-based systems biology approach to
COPD diagnosis would provide several distinct benefits.
The potential for vastly improved disease diagnosis and
classification is evident. As described earlier, whilst the
current method of COPD diagnosis, i.e. spirometry, pro-
vides an indication of airway obstruction, it is insufficient
for accurate disease evaluation, classification and subtyp-
ing. Analysis of biomolecular patterns would provide
details on the molecular and cellular basis underlying the
onset of COPD in an individual facilitating highly accu-
rate disease diagnosis and classification. It would also pro-
vide a means by which the health of a COPD patient
could be efficiently monitored. Inclusion of multiple
molecular species within the molecular fingerprint will
provide far more information than that obtained by anal-
ysis of a single molecular species. Highlighting the stage at
which expression levels of a molecule vary would provide
a greater insight into the causes of disease onset, identify
important pathways for further examination and help
direct future treatment strategies. Having a greater under-
standing of the molecular profiles underlying COPD
would pave the way for personalized medicine where drug
treatments are tailored towards the causal factors of dis-
ease for each individual.
Early symptoms of COPD are chronic cough and sputum
production, which are often ignored by the patients and
physicians, as they are thought to be a normal conse-
quence of smoking [228]. It is not until an individual
experiences further airway obstruction that spirometric
testing will be undertaken, by which time irreversible
damage will have occurred. The longer such symptoms are
ignored, the worse the decline in lung function will be.
With early detection, however, it may be possible to slow
the age-related decline in lung function [229]. Thus, it is
necessary to find ways in which to diagnose COPD when
it is at a stage that is treatable and when smoking cessation
will have an effect on prognosis. An SPR-based systems
biology approach to COPD diagnosis would allow regular
examination of biomolecular patterns in individuals with
a family history of disease or those who are exposed to dis-
ease risk factors. Monitoring such individuals should facil-
itate significant improvements in early disease detection
allowing enhanced drug intervention and anti-smoking
measures at a time when treatment will be more effective,
improving prospects for life expectancy and quality.
Finally, the benefits of biomolecular patterns would be
seen in the field of drug discovery and development.
Adoption of this strategy could be used to circumventRespiratory Research 2009, 10:29 http://respiratory-research.com/content/10/1/29
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some of the problems associated with phase III clinical tri-
als during drug development. Currently the assessment of
therapeutic efficacy in phase III COPD drug trials involves
following a large number of patients, over a long period
of time, in order to measure decline in FEV1. The finding
of a disease specific profile that accurately reflects current
disease activity would reduce the need for such long-term,
expensive, clinical trials [230] by allowing assessment of
the immediate impact of potential drug therapeutics on
disease mechanisms prior to an improvement of out-
wardly detectable symptoms. Improved understanding of
the cellular and molecular basis of COPD pathogenesis
would also potentially provide new therapeutic targets.
Conclusion
Current methods for diagnosing COPD rely on spirome-
try combined with the use of questionnaires and other
arbitrary measures for disease classification. Adopting a
systems biology approach, whereby a disease defining
molecular fingerprint is analysed, would increase the
accuracy of disease diagnosis, aid earlier disease detection,
allow for improved clarification of disease subtypes and
allow automation for community screening.
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